Investigational drug · Phase 3
Vinflunine
Also called: Javlor
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bladder Cancer, Urothelial Cancer, Locally Advanced or Metastatic Unresectable Urothelial Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
34
Any phase or sponsor naming "Vinflunine"
First trial start
2018
Mar 23, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vinflunine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bladder Cancer
- Urothelial Cancer
- Locally Advanced or Metastatic Unresectable Urothelial Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vinflunine" as an intervention, largest first.
- A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast CancerPivotal-lookingTerminated
Pierre Fabre MedicamentIndustry
NCT02054338 · 1,004 participants · Start Jun 2006 · Primary completion Jun 2011
Drug: Vinflunine+Gemcitabine; Paclitaxel+Gemcitabine · For: Advanced Breast Cancer
- A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02302807 · 931 participants · Start Jan 13, 2015 · Primary completion Mar 13, 2017
Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Docetaxel and 2 more · For: Bladder Cancer
Sites: Washington D.C., District of Columbia; Atlanta, Georgia; Las Vegas, Nevada · 217 sites in all
- Trial of Vinflunine Plus Capecitabine in Advanced Breast CancerPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01095003 · 770 participants · Start May 2009 · Primary completion Dec 2011
Drug: Vinflunine plus Capecitabine; Capecitabine · For: Breast Cancer
Sites: Buenos Aires, Argentina; Quilmes, Argentina; Rosario, Argentina · 110 sites in all
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT04527991 · 711 participants · Start Jan 13, 2021 · Primary completion Jul 4, 2025
Drug: Sacituzumab Govitecan-hziy; Paclitaxel and 2 more · For: Locally Advanced or Metastatic Unresectable Urothelial Cancer
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 234 sites in all
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03390504 · 629 participants · Start Mar 23, 2018 · Primary completion Apr 15, 2024
Drug: Erdafitinib; Vinflunine and 2 more · For: Urothelial Cancer
Sites: Anchorage, Alaska; Sacramento, California; St. Helena, California · 345 sites in all
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)Pivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT03474107 · 608 participants · Start Jun 27, 2018 · Primary completion Jul 15, 2020
Drug: Enfortumab Vedotin; Docetaxel and 2 more · For: Ureteral Cancer; Urothelial Cancer; Bladder Cancer
Sites: Orange, California; Sacramento, California; Whittier, California · 158 sites in all
- Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT01091168 · 594 participants · Start Jul 2009 · Primary completion Aug 27, 2012
Drug: vinflunine; Alkylating agent of physician choice registered in cancer · For: Breast Cancer; Metastases
Sites: Buenos Aires, Argentina; Quilmes, Argentina; Rosario, Argentina · 80 sites in all
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07419295 · 590 participants (planned) · Start Apr 23, 2026 · Primary completion Jul 27, 2029
Drug: Sacituzumab tirumotecan; Vinflunine and 4 more · For: Bladder Cancer
Sites: Newport Beach, California; Aurora, Colorado; Highlands Ranch, Colorado · 117 sites in all
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02256436 · 542 participants · Start Oct 22, 2014 · Primary completion Sep 7, 2016
Drug: pembrolizumab; paclitaxel and 2 more · For: Urothelial Cancer
- Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck CancerPivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT02347332 · 459 participants · Start Apr 25, 2014 · Primary completion Oct 20, 2017
Drug: Vinflunine; Methotrexate · For: Recurrent or Metastatic Head and Neck Carcinoma
Sites: Toulouse, France
Newest research
PubMed records naming it or its code names, newest first.
- FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
Maguire WF, Chang E, Mulkey F, et al. · Clin Cancer Res 2026
- Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.
Loriot Y, Matsubara N, Park SH, et al. · ESMO Open 2026
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.
Grudziska M, Czajkowski M, Dolny M, et al. · Cancers (Basel) 2025
- Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
de Wit R, Vaughn DJ, Fradet Y, et al. · Eur Urol 2025
- Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study.
Matsubara N, Loriot Y, Burgess EF, et al. · Clin Genitourin Cancer 2025
- Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.
Powles T, Tagawa S, Vulsteke C, et al. · Ann Oncol 2025
Also in development for Bladder Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.